ClinicalTrials.gg
Enrolling by invitationNCT06327360CAMFPUpdated Apr 5, 2024

Illness Expectations in Pulmonary Fibrosis

An observational study in Pulmonary Fibrosis, sponsored by Fondazione Don Carlo Gnocchi Onlus. Enrolling by invitation at 2 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-05.

Sponsored by Fondazione Don Carlo Gnocchi Onlus · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
130
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Pulmonary Fibrosis with a site in Italy — 11 open to participants now, 15 under way, 4 of them phase 3. Pulmonary Fibrosis · Italy.

Planned enrollment
4th of 14
130 · median 90
Started
2023
with 8 others
Observational
14 of 31
9 open now
Primary completion
2023-10
later than 1 of 14 live
Registered
20th of 31
by date

Among the 31 studies in Pulmonary Fibrosis with a site in Italy, this one is the 4th largest by planned enrollment of the 14 observational ones that give a count, is one of 9 that started in 2023, is one of 14 observational ones, reaches primary completion later than 1 of the 14 other live ones, and was the 20th registered.

Pulmonary Fibrosis

342 studies on the registry are indexed under Pulmonary Fibrosis; 98 are open to participants now.

Browse Pulmonary Fibrosis studies →

Open to participants now

11 of the 31 studies in Pulmonary Fibrosis with a site in Italy are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 71 Pulmonary Fibrosis studies recruiting now, 41 (58%) set no upper age limit and 4 (6%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Pulmonary Fibrosis with a site in Italy, or all of them as a file.
02

Study summary

This study aims to delve into the constructs of illness beliefs and expectations among patients with Pulmonary Fibrosis, exploring how these beliefs and expectations may influence the treatment journey, including oxygen therapy, non-invasive ventilation therapy, and pharmacological treatments.

03

Conditions studied

  • Pulmonary Fibrosis

Keywords

  • Pulmonary Fibrosis
  • Clinical Psychology
  • Rehabilitation Psychology
  • Illness Expectations
  • Illness Perceptions
  • Adherence to treatment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with pulmonary fibrosis, at any stage, of any gender and age

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with pulmonary fibrosis
  • Patients using oxygen therapy
  • Patients using non-invasive ventilation
  • Patients undergoing pharmacological treatment
  • Patients who speak and understand the Italian language

Exclusion criteria

Exclusion Criteria:

  • Patients who do not provide their consent
  • Patients without pulmonary fibrosis
  • Patients with psychiatric disorders or cognitive impaiment
  • Patients who don't speak or understand Italian language
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
130 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with Pulmonary Fibrosis at the Don Gnocchi Foundation (Milan)

    42 patients

    Other: Psychological questionnaires

  • Patients with Pulmonary Fibrosis at the Policlinico (Milano)

    42

    Other: Psychological questionnaires

  • Patients with Pulmonary Fibrosis at the FIMARP ONLUS

    46

    Other: Psychological questionnaires

Interventions

  • OtherPsychological questionnaires

    The questionnaires will be completed at the time of enrollment (T0), and at the 6- and 12-month follow-ups.

06

What researchers measure

Primary outcomes

  1. Adherence to Pharmacological Treatment

    Types of medications taken (Pirfenidone/Nintedanib/Other); assessed as the ratio between the received daily dose (RDD) and the prescribed daily dose (PDD); also evaluated using the Medication Adherence Report Scale (MARS-5), a 5-item questionnaire.

    Time frame: from October 2023 to October 2025

  2. Adherence to Oxygen Therapy

    Use of oxygen and respective quantities (liters/minute at rest and during exertion).

    Time frame: from October 2023 to October 2025

  3. Adherence to Non invasive ventilation

    Use of Non-Invasive Ventilation (nighttime/daytime or both; prescribed and actual hours of usage).

    Time frame: from October 2023 to October 2025

  4. Illness beliefs

    Assessed using the Brief Illness Perception Questionnaire (B-IPQ), a nine-question scale designed to rapidly assess cognitive and emotional representations of the illness. Assessed using the Brief Illness Perception Questionnaire (B-IPQ), a nine-question scale designed to rapidly assess cognitive and emotional representations of the illness.

    Time frame: from October 2023 to October 2025

  5. Pharmacological treatment Beliefs

    Assessed using the Beliefs about Medicines Questionnaire (BMQ), a tool designed to evaluate individuals' beliefs about medications. It has been validated for use in patients with chronic illnesses and has been shown to predict treatment adherence in other groups, such as individuals with asthma.

    Time frame: from October 2023 to October 2025

  6. Illness Expectations

    Specific questions formulated to assess explicit illness expectations in Pulmonary Fibrosis are proposed.

    Time frame: from October 2023 to October 2025

  7. Illness Cognitions

    Illness Cognition Questionnaire (ICQ), a questionnaire assessing three ways of cognitively evaluating the stressful and adverse nature of a chronic illness: helplessness, acceptance, and perceived benefits.

    Time frame: from October 2023 to October 2025

Secondary outcomes

  1. Socio-demographic variables

    Gender, age, smoking status, and number of cigarettes smoked per day. Additionally, factors such as family history of respiratory diseases, alcohol use (frequency), physical activity (frequency and type), level of education, marital status, onset of initial symptoms, and date of diagnosis will be considered.

    Time frame: from October 2023 to October 2025

  2. Clinical and medical data

    Weight and height (for calculation of Body Mass Index, BMI); comorbidities (diabetes, hypertension, hypercholesterolemia, presence of other conditions), perceived symptoms (e.g., dyspnea, cough, chest pain, fatigue and weakness, muscle and joint pains, weight loss...). Additionally, parameters from respiratory function tests (particularly Forced Vital Capacity (FVC) and Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO), arterial blood gas analysis) will be recorded. These data will be extracted from the latest available medical report and therefore from the last pulmonary visit conducted as part of routine clinical practice (please note that medical visits paid for by this project are not included).

    Time frame: from October 2023 to October 2025

07

Study locations

2 sites
08

References and documents

Publications

  • Raghu G, Chen SY, Hou Q, Yeh WS, Collard HR. Incidence and prevalence of idiopathic pulmonary fibrosis in US adults 18-64 years old. Eur Respir J. 2016 Jul;48(1):179-86. doi: 10.1183/13993003.01653-2015. Epub 2016 Apr 28. PubMed 27126689 ↗
  • Meyer KC. Pulmonary fibrosis, part I: epidemiology, pathogenesis, and diagnosis. Expert Rev Respir Med. 2017 May;11(5):343-359. doi: 10.1080/17476348.2017.1312346. Epub 2017 Apr 10. PubMed 28345383 ↗
  • Wolters PJ, Blackwell TS, Eickelberg O, Loyd JE, Kaminski N, Jenkins G, Maher TM, Molina-Molina M, Noble PW, Raghu G, Richeldi L, Schwarz MI, Selman M, Wuyts WA, Schwartz DA. Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic? Lancet Respir Med. 2018 Feb;6(2):154-160. doi: 10.1016/S2213-2600(18)30007-9. PubMed 29413083 ↗
  • Ley B, Collard HR. Epidemiology of idiopathic pulmonary fibrosis. Clin Epidemiol. 2013 Nov 25;5:483-92. doi: 10.2147/CLEP.S54815. PubMed 24348069 ↗
  • Broadbent E, Petrie KJ, Main J, Weinman J. The brief illness perception questionnaire. J Psychosom Res. 2006 Jun;60(6):631-7. doi: 10.1016/j.jpsychores.2005.10.020. PubMed 16731240 ↗
  • Evers AW, Kraaimaat FW, van Lankveld W, Jongen PJ, Jacobs JW, Bijlsma JW. Beyond unfavorable thinking: the illness cognition questionnaire for chronic diseases. J Consult Clin Psychol. 2001 Dec;69(6):1026-36. PubMed 11777106 ↗
  • Agarwal P, Lin J, Muellers K, O'Conor R, Wolf M, Federman AD, Wisnivesky JP. A structural equation model of relationships of health literacy, illness and medication beliefs with medication adherence among patients with chronic obstructive pulmonary disease. Patient Educ Couns. 2021 Jun;104(6):1445-1450. doi: 10.1016/j.pec.2020.11.024. Epub 2020 Nov 25. PubMed 33308880 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Oct 2023, 0 months.

Of 60 observational studies under Pulmonary Fibrosis, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 111. This study's 0 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2024
First posted
Mar 25, 2024
StartActual
Oct 10, 2023
Primary completionActual
Oct 10, 2023
CompletionEst.
Oct 1, 2025
Last update
Apr 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06327360
Collaborators
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, FIMARP ONLUS - FEDERAZIONE ITALIANA IPF E MALATTIE POLMONARI RARE
Responsible party
Eleonora Volpato (Clinical Professor, Fondazione Don Carlo Gnocchi Onlus) — Principal investigator
First posted
Mar 25, 2024
Start date
Oct 10, 2023
Primary completion
Oct 10, 2023
Completion
Oct 1, 2025 (estimated)
Last update
Apr 5, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion